Somatic symptoms in treatment-resistant depression

George I. Papakostas; Timothy Petersen; John Denninger; Shamsah B. Sonawalla; Yasmin Mahal; Jonathan E. Alpert; Andrew A. Nierenberg; Maurizio Fava

doi:10.1016/S0165-1781(03)00063-5

Somatic symptoms in treatment-resistant depression

George I. Papakostas, Timothy Petersen, John Denninger, Shamsah B. Sonawalla, Yasmin Mahal, Jonathan E. Alpert, Andrew A. Nierenberg, Maurizio Fava

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

The purpose of this work was to study the prevalence of somatic symptoms in patients with treatment-resistant depression (TRD) and their impact on the response to antidepressant treatment. Somatic symptoms were assessed during the screen visit with the Symptom Questionnaire (SQ) somatic symptom (SQ-SS) and somatic well-being sub-scales (SQ-SWB) in 40 patients with TRD enrolled in a 6-week open trial of nortriptyline. A logistic regression was used to test whether SQ-SS or SQ-SWB scores predicted clinical response to nortriptyline. Ninety-five percent of patients reported at least one somatic symptom. Higher SQ-SS scores during the screen visit predicted poorer response to nortriptyline. There was a trend for lower SQ-SWB scores to predict poor response to nortriptyline. None of the patients with SQ-SS scores above the mean for the sample responded to nortriptyline. The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance.

Original language	English (US)
Pages (from-to)	39-45
Number of pages	7
Journal	Psychiatry Research
Volume	118
Issue number	1
DOIs	https://doi.org/10.1016/S0165-1781(03)00063-5
State	Published - May 1 2003
Externally published	Yes

Keywords

Antidepressants
Nortriptyline
Response prediction
Symptom Questionnaire

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0165-1781(03)00063-5

Cite this

@article{a87b5a017ba14dddbd293f3ab3b1d384,

title = "Somatic symptoms in treatment-resistant depression",

abstract = "The purpose of this work was to study the prevalence of somatic symptoms in patients with treatment-resistant depression (TRD) and their impact on the response to antidepressant treatment. Somatic symptoms were assessed during the screen visit with the Symptom Questionnaire (SQ) somatic symptom (SQ-SS) and somatic well-being sub-scales (SQ-SWB) in 40 patients with TRD enrolled in a 6-week open trial of nortriptyline. A logistic regression was used to test whether SQ-SS or SQ-SWB scores predicted clinical response to nortriptyline. Ninety-five percent of patients reported at least one somatic symptom. Higher SQ-SS scores during the screen visit predicted poorer response to nortriptyline. There was a trend for lower SQ-SWB scores to predict poor response to nortriptyline. None of the patients with SQ-SS scores above the mean for the sample responded to nortriptyline. The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance.",

keywords = "Antidepressants, Nortriptyline, Response prediction, Symptom Questionnaire",

author = "Papakostas, {George I.} and Timothy Petersen and John Denninger and Sonawalla, {Shamsah B.} and Yasmin Mahal and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Maurizio Fava",

note = "Funding Information: The research reported was supported in part by grant R29 MH46952 (AAN) from the National Institute of Mental Health.",

year = "2003",

month = may,

day = "1",

doi = "10.1016/S0165-1781(03)00063-5",

language = "English (US)",

volume = "118",

pages = "39--45",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Somatic symptoms in treatment-resistant depression

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Denninger, John

AU - Sonawalla, Shamsah B.

AU - Mahal, Yasmin

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

N1 - Funding Information: The research reported was supported in part by grant R29 MH46952 (AAN) from the National Institute of Mental Health.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The purpose of this work was to study the prevalence of somatic symptoms in patients with treatment-resistant depression (TRD) and their impact on the response to antidepressant treatment. Somatic symptoms were assessed during the screen visit with the Symptom Questionnaire (SQ) somatic symptom (SQ-SS) and somatic well-being sub-scales (SQ-SWB) in 40 patients with TRD enrolled in a 6-week open trial of nortriptyline. A logistic regression was used to test whether SQ-SS or SQ-SWB scores predicted clinical response to nortriptyline. Ninety-five percent of patients reported at least one somatic symptom. Higher SQ-SS scores during the screen visit predicted poorer response to nortriptyline. There was a trend for lower SQ-SWB scores to predict poor response to nortriptyline. None of the patients with SQ-SS scores above the mean for the sample responded to nortriptyline. The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance.

AB - The purpose of this work was to study the prevalence of somatic symptoms in patients with treatment-resistant depression (TRD) and their impact on the response to antidepressant treatment. Somatic symptoms were assessed during the screen visit with the Symptom Questionnaire (SQ) somatic symptom (SQ-SS) and somatic well-being sub-scales (SQ-SWB) in 40 patients with TRD enrolled in a 6-week open trial of nortriptyline. A logistic regression was used to test whether SQ-SS or SQ-SWB scores predicted clinical response to nortriptyline. Ninety-five percent of patients reported at least one somatic symptom. Higher SQ-SS scores during the screen visit predicted poorer response to nortriptyline. There was a trend for lower SQ-SWB scores to predict poor response to nortriptyline. None of the patients with SQ-SS scores above the mean for the sample responded to nortriptyline. The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance.

KW - Antidepressants

KW - Nortriptyline

KW - Response prediction

KW - Symptom Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=0037621668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037621668&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(03)00063-5

DO - 10.1016/S0165-1781(03)00063-5

M3 - Article

C2 - 12759160

AN - SCOPUS:0037621668

VL - 118

SP - 39

EP - 45

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -

Somatic symptoms in treatment-resistant depression

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this